Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK2 | O95069 | 2/20 | 0.44 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 12/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 12/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1663491 | 0.88 | AKR1C3 (0.40) | KCNK2KCNK10AKR1C3AKR1C2ALDH1A1 | |
| SCHEMBL1663328 | 0.85 | PDK1 (0.39) | ALDH1A1MEN1KMT2ANPSR1KDM4E | |
| SCHEMBL1663199 | 0.83 | AKR1C3 (0.37) | KCNK2KCNK10AKR1C3AKR1C2ALDH1A1 | |
| SCHEMBL1665765 | 0.83 | ALDH1A1 (0.47) | KCNK2KCNK10AKR1C3AKR1C2ALDH1A1 | |
| SCHEMBL21487757 | 0.75 | KDM4E (0.42) | AKR1C2ALDH1A1KDM4E | |
| SCHEMBL8550609 | 0.74 | GRIK1 (0.56) | MEN1KMT2AGRIK1 | |
| SCHEMBL1663492 | 0.73 | ALDH1A1 (0.46) | ALDH1A1MEN1PKMKMT2AKDM4E | |
| SCHEMBL9743950 | 0.72 | GRIK1 (0.56) | KCNK2KCNK10ALDH1A1MEN1KMT2A | |
| SCHEMBL5209585 | 0.72 | KDM4E (0.63) | KCNK2KCNK10ALDH1A1KMT2AKDM4E | |
| SCHEMBL9507318 | 0.71 | ALDH1A1 (0.47) | KCNK2KCNK10ALDH1A1MEN1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305652-A2 | Trisubstituted quinazolinone derivatives as vanilloid antagonists | Novartis AG (CH) | 2011-04-06 | — | — | EP | disclosed |
| EP-2305652-A2 | Trisubstituted quinazolinone derivatives as vanilloid antagonists | Novartis AG (CH) | 2011-04-06 | — | — | EP | disclosed |
| US-20090082365-A1 | Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists | NOVARTIS AG | 2009-03-26 | — | — | US | disclosed |
| US-20090082365-A1 | Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists | NOVARTIS AG | 2009-03-26 | — | — | US | disclosed |
| EP-1963283-A2 | TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007065662-A2 | TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082365-A1 | Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists | TRPV1, TRPV3, TRPV5 | KCNK2 234/4885KCNK10 270/4885AKR1C3 1372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.